Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinay Vanguru

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Australian Prescriber|December 6, 2023
Chimeric antigen receptor T-cell therapyCale Burge, Vinay Vanguru, Phoebe Joy Ho
Asia-Pacific Journal of Clinical Oncology|December 23, 2022
Hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) in a patient with oncogene-addicted metastatic non-small cell lung cancer (NSCLC) following combination chemotherapy-immunotherapySarah Heynemann, Vinay Vanguru, Stephen Adelstein, et al.
Pathology|December 22, 2021
Red cell transfusion in alloimmunised allogeneic stem cell transplant patientsJacinta Perram, Vinay Vanguru, Lynette Ackerman, et al.
Medical Mycology Case Reports|March 1, 2024
Haemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patientMallory Morton, Vinay Vanguru, Joo-Shik Shin, et al.
BMC Nephrology|August 14, 2020
Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case reportJack E Heron, Mark Bloch, Vinay Vanguru, et al.
Pathology|November 22, 2023
Flow cytometric immunophenotype of CAR T-cells in pleural fluid and differences with peripheral blood CAR T-cells in a patient with large B-cell lymphomaEric Wenlong Li, Esther Aklilu, Alison Potter, et al.
Transplantation and Cellular Therapy|May 11, 2026
Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone ProphylaxisGemma K Reynolds, Mark R Dowling, Jose Valencia-Klug, et al.
Frontiers in Oncology|September 4, 2025
Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimizationPhoebe Joy Ho, Vinay Vanguru, Cale S Burge, et al.
European Journal of Haematology|July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapiesEric Wenlong Li, Esther Jones, Christian Bryant, et al.
Transplantation and Cellular Therapy|January 8, 2025
Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More TherapiesEdward Abadir, Rebecca Wayte, Wenlong Li, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Australian Prescriber|December 6, 2023
Chimeric antigen receptor T-cell therapyCale Burge, Vinay Vanguru, Phoebe Joy Ho
Asia-Pacific Journal of Clinical Oncology|December 23, 2022
Hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) in a patient with oncogene-addicted metastatic non-small cell lung cancer (NSCLC) following combination chemotherapy-immunotherapySarah Heynemann, Vinay Vanguru, Stephen Adelstein, et al.
Pathology|December 22, 2021
Red cell transfusion in alloimmunised allogeneic stem cell transplant patientsJacinta Perram, Vinay Vanguru, Lynette Ackerman, et al.
Medical Mycology Case Reports|March 1, 2024
Haemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patientMallory Morton, Vinay Vanguru, Joo-Shik Shin, et al.
BMC Nephrology|August 14, 2020
Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case reportJack E Heron, Mark Bloch, Vinay Vanguru, et al.
Pathology|November 22, 2023
Flow cytometric immunophenotype of CAR T-cells in pleural fluid and differences with peripheral blood CAR T-cells in a patient with large B-cell lymphomaEric Wenlong Li, Esther Aklilu, Alison Potter, et al.
Transplantation and Cellular Therapy|May 11, 2026
Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone ProphylaxisGemma K Reynolds, Mark R Dowling, Jose Valencia-Klug, et al.
Frontiers in Oncology|September 4, 2025
Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimizationPhoebe Joy Ho, Vinay Vanguru, Cale S Burge, et al.
European Journal of Haematology|July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapiesEric Wenlong Li, Esther Jones, Christian Bryant, et al.
Transplantation and Cellular Therapy|January 8, 2025
Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More TherapiesEdward Abadir, Rebecca Wayte, Wenlong Li, et al.
Pageof 2